AUA
  • Program
  • Register
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Topics
  • Meeting Coverage
  • Guidelines
  • Industry Highlights
  • Science & Technology Hall
  • Photo Gallery
Resources
  • Program
  • Register
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
Sep 12, 2021

Plenary: Sacral neuromodulation shows promise in treating pediatric bladder dysfunction

Careful patient selection for this treatment is essential.


Use Bladder

Pediatric bladder dysfunction was the topic during Sunday morning’s Plenary Session.

Moderated by Christopher S. Cooper, MD, FAAP, FACS, professor and vice chair of urology at the University of Iowa, this “Second Opinion Cases” session featured three different presentations on treatment of pediatric bladder dysfunction.

Seth A. Alpert, MD, a member of the Department of Pediatric Urology at Nationwide Children’s Hospital and a clinical associate professor of urology at The Ohio State University Wexner Medical Center, presented the case of a 9-year-old girl with a long history of urgency and frequency accompanied by both daytime and nighttime wetting and constipation.

“She’d tried many different anticholinergics in the past but had not shown significant improvement,” he said. “Like many of these children, she took MiraLAX® daily for constipation issues.”

Dr. Alpert said that after both a renal ultrasound and MRI came back clear, he discussed options with the family. They chose to treat her refractory voiding symptoms and history of constipation with sacral neuromodulation (SNM).

SNM is not approved for patients younger than 16 for either urinary or bowel control indications. That said, the off-label treatment has shown promise.

“In children, SNM is always a two-stage outpatient surgical treatment with a two-week trial period to look for over 50% improvement,” he said. “This particular patient had about an 80% improvement in her voiding symptoms at two weeks, so we moved forward.”

Eventually, with her permanent battery in place, the patient’s symptoms improved to nearly 95%,” Dr. Alpert said.

“Over time, she did quite well,” he said. “She’s been coming back to clinic about every six months or so for device interrogation. Four years later, she’s now 13, and it’s coming up on the lifecycle of the battery and it will be time for replacing the battery or doing a trial with the battery off for a year or two.”

Dr. Alpert said the takeaways from this case, as well as the supporting research, indicate that SNM is safe and effective for refractory non-neurogenic bladder and/or bowel dysfunction in pediatric patients.

Dr. Alpert said careful patient selection is essential, and most children with refractory overactive bladder symptoms will not qualify for treatment until they fail treatment with two or more anticholinergics.

“It is also important to note that SNM is not meant to be a permanent therapy,” he said. “You should consider device removal when there is no return of symptoms after a trial where the device is turned off for more than 6 months.”

Stacy T. Tanaka, MD, MS, a professor of urology and pediatrics at Vanderbilt University Medical Center, gave a presentation regarding urinary incontinence (UI) in female athletes.

She said UI has an increased association with eating disorder risk and low energy availability in female athletes.

“There is a high prevalence of UI in young female athletes, which is often incorrectly accepted as normal or unavoidable, she said. “The risk of eating disorders in female athletes with UI offers an opportunity for screening or partnering with primary care. 

Israel Franco, MD, director of the Yale Medicine Pediatric Bladder and Continence Program, discussed the case of a 16-year-old male who presented with intermittent, ongoing pain in his groin that occurred 25 times a day, but only lasted “six to seven seconds.”

Dr. Franco said he discovered that the cause of the issue was bladder neck dysfunction, “which is only discernable by doing a uroflow with electromyography.”

“Many of these patients void with large volumes due to autonomic/sympathetic increased tone,” he said. “This leads to enlarged bladder capacity, bladder neck dysfunction, constipation and orthostatic dizziness. In addition, many patients have underlying attention deficit hyperactivity disorder, anxiety or depression, and correction of the condition is critical to seeing improvement.”

Visit AUA2021 Daily News Online for more articles.

Interesting Stories
Register for the Career Fair at AUA2025
Sponsored by AUA
Register for the Career Fair at AUA2025
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Sponsored by Sun Pharma
YONSA® (abiraterone acetate) Holds a Full House of Benefits—See Booth 1222
Book your AUA2025 housing now
Sponsored by AUA
Book your AUA2025 housing now
More Content
Getty Images 1208851295
AUA2022
Save the date
Jan 31, 2022
Aua Wrap 04
AUA2021
AUA2021 On Demand: see what’s streaming
Sep 22, 2021
Aua Wrap 03
AUA2021
Satellite symposia bring expert insights
Sep 22, 2021
Aua Wrap 01
AUA2021
Education and training for young urologists
Sep 22, 2021
Getty Images 1199215126
AUA2021
Claim your CME
Sep 22, 2021
Aua Wrap 05
AUA2021
Read all about it
Sep 22, 2021
Aua Tv
AUA2021
Must-see TV
Sep 22, 2021
Getty Images 185224486
AUA2021
AUA2021: By the numbers
Sep 15, 2021
Toni K. Choueiri, MD
AUA2021
Late-breaking science
Sep 15, 2021
Ian M. Thompson Jr., MD
AUA2021
Award winners
Sep 15, 2021
Tips And Tricks
AUA2021
Guideline updates
Sep 15, 2021
Ai
AUA2021
New technology
Sep 15, 2021
AUA
Twitter X icon Facebook iconInstagram iconYouTube iconLinkedIn icon
© 2025 Ascend Media. All rights reserved.